SCHEMBL16655277

SCHEMBL16655277

OCc1nn(C2CCCCO2)cc1-c1ccnc2[nH]ccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKB Q96GD4 5/20 0.44
AURKA O14965 4/20 0.44
NUDT1 P36639 1/20 0.41
PIK3C3 Q8NEB9 1/20 0.41
INCENP Q9NQS7 1/20 0.40
TPX2 Q9ULW0 1/20 0.40
CIT O14578 3/20 0.39
JAK2 O60674 3/20 0.38
JAK3 P52333 2/20 0.38
IKBKB O14920 2/20 0.38
CHUK O15111 2/20 0.38
DAPK3 O43293 1/20 0.38
PRKD3 O94806 1/20 0.38
MAP4K4 O95819 1/20 0.38
PAK4 O96013 1/20 0.38
CSF1R P07333 1/20 0.38
RET P07949 1/20 0.38
IGF1R P08069 1/20 0.38
FGFR1 P11362 1/20 0.38
PRKACA P17612 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16655428 0.83 AURKB (0.46) AURKBAURKANUDT1PIK3C3INCENP
SCHEMBL16655108 0.82 AURKB (0.42) AURKBAURKANUDT1PIK3C3INCENP
SCHEMBL16655160 0.80 NUDT1 (0.46) AURKBAURKANUDT1JAK3BRAF
SCHEMBL1647776 0.80 MAPK14 (0.59) AURKBAURKAPIK3C3INCENPIGF1R
SCHEMBL1648278 0.79 AURKB (0.48) AURKBAURKAPIK3C3INCENPTPX2
SCHEMBL16655062 0.79 AURKB (0.57) AURKBAURKANUDT1PIK3C3INCENP
SCHEMBL1646703 0.77 NUDT1 (0.53) AURKBAURKANUDT1PIK3C3JAK2
SCHEMBL1648143 0.75 BRAF (0.46) AURKBAURKANUDT1JAK2JAK3
SCHEMBL25179442 0.69 CYP4F2 (0.37) FGFR1KDRBRAFCD274
SCHEMBL31413853 0.69 ALDH1A1 (0.36) RETFGFR1KDRCD274

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9440977-B2 Compositions, uses and methods for their preparation SHENGYUAN PHARMACEUTICAL GUANGZHOU LTD CO. (CN) 2016-09-13 US disclosed
US-9440977-B2 Compositions, uses and methods for their preparation SHENGYUAN PHARMACEUTICAL GUANGZHOU LTD CO. (CN) 2016-09-13 US disclosed
EP-3057972-A1 NOVEL COMPOSITIONS, USES AND METHODS FOR THEIR PREPARATION Jin, V (US) 2016-08-24 EP disclosed
US-20160229855-A1 NOVEL COMPOSITIONS, USES AND METHODS FOR THEIR PREPARATION Jin, Bohan (US) 2016-08-11 US disclosed
US-20160229855-A1 NOVEL COMPOSITIONS, USES AND METHODS FOR THEIR PREPARATION Jin, Bohan (US) 2016-08-11 US disclosed
WO-2015057695-A1 NOVEL COMPOSITIONS, USES AND METHODS FOR THEIR PREPARATION JIN BOHAN (US) 2015-04-23 WO disclosed
WO-2015057695-A1 NOVEL COMPOSITIONS, USES AND METHODS FOR THEIR PREPARATION JIN BOHAN (US) 2015-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160229855-A1 NOVEL COMPOSITIONS, USES AND METHODS FOR THEIR PREPARATION LIPA, PNLIP, LIPC AURKB 4636/4885AURKA 4788/4885NUDT1 207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.